Results 41 to 50 of about 4,942 (259)

siRNA drug Leqvio (inclisiran) to lower cholesterol

Trends in Pharmacological Sciences, 2022
Julia M. Migliorati, Jing Jin, Xiao‐bo Zhong   +2 more
openalex   +4 more sources

Inclisiran : How widely and when should we use it? [PDF]

, 2022
Purpose of Review Plasma levels of LDL cholesterol (LDL-C) are causally associated with cardiovascular risk. Reducing LDL-C results in a decreased incidence of cardiovascular events, proportionally to the absolute reduction in LDL-C.
Catapano, Alberico Luigi, Pirillo, Angela   +1 more
core   +2 more sources

Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review

Cardiovascular Therapeutics, 2022
As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide.
Iveta Merćep, Nikolina Friščić, Dominik Strikić, Željko Reiner   +3 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes:A systematic review and meta-analysis [PDF]

, 2019
Background: To evaluate the effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on major adverse cardiovascular events (MACE).Methods: Our systematic review included randomised controlled trials if they studied PCSK9 inhibitors in ...
Du, Heyue, Gao, Haihui, Hao, Xiaoting, Kwong, Joey S. W., Lang, Chim, Li, Jianshu, Li, Ling, Li, Qianrui, Li, Sheyu, Li, Xiaodan, Mordi, Ify, Nemeth, Imola, Rao, Li, Su, Na, Tian, Haoming, Vandvik, Per Olav, Yang, Xueli, Zhang, Longhao   +17 more
core   +3 more sources

A RANDOMIZED STUDY TO COMPARE LDL-C-LOWERING EFFECTS OF INCLISIRAN WITH USUAL CARE VS USUAL CARE ALONE IN PATIENTS WITH RECENT HOSPITALIZATION FOR AN ACUTE CORONARY SYNDROME: RATIONALE AND DESIGN OF THE VICTORION-INCEPTION TRIAL

American Journal of Preventive Cardiology, 2023
Therapeutic Area: CVD Prevention – Primary and Secondary Background: Patients are at high risk for a recurrent cardiovascular (CV) event in the first year following acute coronary syndrome (ACS).
Jeffrey L. Anderson, MD, Ann Marie Navar, MD, PhD, Neeraja Balachander, MBBS, PhD, MS, Nihar R. Desai, MD, MPH, Kirk U. Knowlton, MD   +4 more
doaj   +1 more source

PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition. [PDF]

Int J Mol Sci
Cardiotoxicity related to anthracyclines and trastuzumab represents a significant clinical challenge in cancer therapy, often limiting treatment efficacy and patient survival.
Quagliariello V, Berretta M, Bisceglia I, Iovine M, Barbato M, Arianna R, Canale ML, Paccone A, Inno A, Scherillo M, Oliva S, Cadeddu Dessalvi C, Mauriello A, Maurea C, Fonderico C, Maratea AC, Gabrielli D, Maurea N.   +17 more
europepmc   +2 more sources

Nutraceuticals as therapeutic agents for atherosclerosis [PDF]

, 2018
Atherosclerosis, a chronic inflammatory disorder of medium and large arteries and an underlying cause of cardiovascular disease (CVD), is responsible for a third of all global deaths.
Moss, Joe, Ramji, Dipak, Williams, Jessica   +2 more
core   +2 more sources

Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm? [PDF]

, 2023
Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are low-density lipoprotein cholesterol (LDL-C)-lowering drugs that play a critical role in lipoprotein clearance and metabolism.
Agarwal, Manyoo A, Almahmeed, Wael, Ciaccio, Marcello, Giglio, Rosaria Vincenza, Klisic, Aleksandra, Muzurović, Emir M, Patti, Angelo Maria, Rizzo, Manfredi, Toth, Peter P   +8 more
core   +1 more source

Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial. [PDF]

Circulation
BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a genetic disease characterized by high levels of low-density lipoprotein cholesterol (LDL-C) present from birth, leading to early-onset and progressive atherosclerotic cardiovascular disease.
Wiegman A, Peterson AL, Hegele RA, Bruckert E, Schweizer A, Lesogor A, Wang Y, Defesche J.   +7 more
europepmc   +2 more sources

Up-To-Date Pharmacological Topics on the Medication of Statin and Inclisiran [PDF]

, 2021
Up-to-date pharmacological topics for inclisiran and statin for dyslipidemia are described. The efficacy of inclisiran has been reported for reduction of LDL-C values. Inclisiran has been involved in gene silencing, which brings selective inhibition of a
Bando, Hiroshi
core